gapmeroligonukleotider

Gapmeroligonucleotides, often shortened to gapmers, are synthetic nucleic acid molecules designed to bind to specific RNA targets. They consist of a central region of deoxyribonucleotides, flanked by oligonucleotide sequences of ribonucleotides or modified ribonucleotides. This unique structure allows gapmers to function through various mechanisms, primarily by modulating gene expression.

The central deoxyribonucleotide gap is crucial for their mode of action. When a gapmer binds to its target mRNA, the deoxyribonucleotide sequence recruits RNase H, an enzyme that degrades RNA. This enzymatic degradation of the target mRNA leads to a reduction in the production of the corresponding protein, effectively silencing gene expression. This process is known as antisense inhibition.

Gapmers can also be designed with modifications to the flanking regions to enhance their stability, cellular uptake, and binding affinity. These modifications can include phosphorothioate linkages or the incorporation of 2'-O-methyl or locked nucleic acids (LNAs). Such modifications can improve the therapeutic potential of gapmers.

The primary application of gapmers is in the development of antisense oligonucleotide therapies. They are being investigated and used to treat a range of diseases caused by the overproduction or aberrant expression of specific proteins. Examples include certain genetic disorders, viral infections, and cancers. Their ability to selectively target and reduce the levels of specific disease-associated RNA molecules makes them a valuable tool in molecular medicine.